Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients
Shots:
- Sorrento receives the US FDA’s clearance to proceed P-I clinical study of STI-1499 (COVI-GUARD) in hospitalized COVID-19 patients. The company receives the FDA’s notice to proceed the patient enrollment
- The trial is anticipated to enroll rapidly and is expected to be followed by large trials targeting a potential EUA submission as early as before the end of 2020. STI-1499 has demonstrated 100% in vitro neutralizing effect against SARS-CoV-2 in preclinical studies
- The highest proposed dose (200mg/patient) in P-I study is a lower dose than currently being tested for other known SARS-CoV-2 targeted Abs or Ab cocktails in studies. Sorrento has initiated cGMP manufacturing to produce 50-000 doses in anticipation of a EUA
Ref: Sorrento | Image: Euractive
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com